糖皮质激素玻璃体给药在糖尿病黄斑水肿治疗中的应用  

Application of intravitreal glucocorticoid in diabetic macular edema

作　　者：王净信[1] 孙京华[1] 

机构地区：[1]华中科技大学同济医学院附属同济医院眼科,武汉430030

出　　处：《眼科研究》2005年第5期553-556,共4页Chinese Ophthalmic Research

摘　　要：糖尿病黄斑水肿主要由于血管通透性的增加、血-视网膜屏障破坏、视网膜内或视网膜下液体的异常积聚,导致患者视力损害。以往主要以激光光凝治疗,但其疗效不确切。研究表明玻璃体注射糖皮质激素可有效治疗各种原因引起的黄斑水肿,糖皮质激素因易进入细胞内与胞浆广泛的激素受体结合,形成各种蛋白质,发挥生物效应,进而稳定血-视网膜屏障。但需注意视网膜毒性效应,引起眼压升高以及白内障发生的可能性。综述了糖皮质激素治疗黄斑水肿的作用机制及其在糖尿病黄斑水肿治疗中的研究进展。Diabetic macutar edema （DME） results in vision acuity decreasing mainly due to increasing permeability of blood vessels, destruction of blood retina barrier（BRB） and abnormally fluid aggregation in inter-retina or the subretina. The major therapeutical method is laser photocoagulation. However, its curative effect is not significant, lntravitreal injection of glucocorticoid is a new promising approach to management of DME. Glucocorticosteroid enter cells through binding its receptors and displaying biological effect, then stable blood retina barrier, on the other hand, the side effect such as retina toxicity, high intraocular pressure and cataract formation should be closely monitored.

关 键 词：糖皮质激素 糖尿病视网膜病变 水肿 玻璃体腔注射 

分 类 号：R774.5[医药卫生—眼科]